Last reviewed · How we verify
Oxybuprocaine 0.4%
Oxybuprocaine 0.4% is a Small molecule drug developed by London Vision Clinic. It is currently in Phase 1 development.
Oxybuprocaine 0.4% is used in clinical trials for conditions such as pain, subconjunctival hemorrhage, and intravitreal injection. The exact mechanism of action of oxybuprocaine 0.4% is unknown.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Oxybuprocaine 0.4% |
|---|---|
| Sponsor | London Vision Clinic |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- eye pruritus
- Injury corneal
Key clinical trials
- Efficacy and Safety of Chloroprocaine 3% Gel and Oxybuprocaine 0.4% Eye Drops Anesthesia in Pediatric Population (PHASE3)
- Identification of Cellular Biomarkers of Rare Eye Diseases in Adults (NA)
- The Role of Adjuvant Corneal Crosslinking in the Management of Infective Keratitis (EARLY_PHASE1)
- Effectiveness of Intravitreal Injection of Aflibercept 8 mg in Resistant Diabetic Macular Edema, Retinal Vein Occlusion and Myopic Choroidal Neovascularisation Patients (EARLY_PHASE1)
- Change in Ocular Perfusion After Intravitreal Anti-VEGF in Patients with Age-related Maculopathy or Diabetic Macula Edema
- Hemodynamic Response to Pain During Retinopathy Of Prematurity Screening (PHASE4)
- Therapeutic Efficacy and Safety of Non-Invasive RF Treatment in Refractory MGD (NA)
- VisuMax Femtosecond Laser Small Incision Lenticule Extraction for the Correction of High Myopia (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oxybuprocaine 0.4% CI brief — competitive landscape report
- Oxybuprocaine 0.4% updates RSS · CI watch RSS
- London Vision Clinic portfolio CI
Frequently asked questions about Oxybuprocaine 0.4%
What is Oxybuprocaine 0.4%?
Who makes Oxybuprocaine 0.4%?
What development phase is Oxybuprocaine 0.4% in?
What are the side effects of Oxybuprocaine 0.4%?
Related
- Manufacturer: London Vision Clinic — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing